HC Wainwright Issues Optimistic Estimate for Curis Earnings

Curis, Inc. (NASDAQ:CRIS) – Equities researchers at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for Curis in a research report issued on Monday, August 17th. HC Wainwright analyst S. Nik now expects that the biotechnology company will post earnings of ($2.29) per share for the quarter, up from their previous forecast of ($5.87). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Curis’ current full-year earnings is ($33.29) per share. HC Wainwright also issued estimates for Curis’ Q4 2026 earnings at ($1.50) EPS, FY2026 earnings at ($15.65) EPS and FY2027 earnings at ($57.10) EPS.

CRIS has been the topic of several other research reports. Wall Street Zen cut shares of Curis to a “strong sell” rating in a research report on Saturday, August 8th. Zacks Research lowered Curis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Curis currently has an average rating of “Reduce” and a consensus target price of $43.00.

Curis Trading Down 5.6%

Shares of CRIS opened at $1.70 on Wednesday. The stock has a 50-day moving average price of $5.54 and a 200-day moving average price of $11.45. The company has a market cap of $3.55 million, a PE ratio of -0.12 and a beta of 3.13. Curis has a 12-month low of $1.54 and a 12-month high of $39.00.

Curis (NASDAQ:CRIS) last announced its earnings results on Friday, August 14th. The biotechnology company reported ($4.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.95) by $2.93. Curis had a negative return on equity of 4,169.81% and a negative net margin of 80.29%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Curis in the 2nd quarter valued at about $28,000. XTX Topco Ltd purchased a new stake in Curis during the 4th quarter valued at about $26,000. Squarepoint Ops LLC grew its position in Curis by 46.2% during the 4th quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 27,343 shares during the last quarter. Jane Street Group LLC grew its position in Curis by 71.8% during the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 10,586 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Curis by 37.3% in the 4th quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 65,404 shares during the period. 29.97% of the stock is owned by institutional investors.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.